Company / Operating Cash Flow per Share
Dianthus Therapeutics, Inc. /DE/ Operating Cash Flow per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow per Share
-$4.15
FY2025
5-year range
-$33.25 / -$1.08
FY2021-FY2025
Trend
-66.7%
vs FY2024
Sector context
#192 of 212
Health Care
What the data says
Among 212 Health Care companies, Dianthus Therapeutics, Inc. /DE/ is in the bottom 9% for operating cash flow per share. Operating Cash Flow per Share has fluctuated over the past 10 years, ranging from $-43.70 in FY2016 to $-1.08 in FY2021.
Based on SEC 10-K filings.
-4.15 in FY2025.
Improved from $-7.15 to $-4.15 over the past 2 years.
Health Care sector context is included.
Operating Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 9% in Health CareTop 91% of 212This company -$4.15 Sector average $5.28
▼
-178.6% below sector average
Key checks
Key Insights
- In FY2025, operating cash flow per share decreased 66.7% year-over-year.
- Ranks #192 out of 212 companies in the Health Care sector.
- Peak operating cash flow per share was recorded in FY2021.
- Lowest operating cash flow per share in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 4.46 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$4.15 | -66.7% |
| FY2024 | -$2.49 | +65.2% |
| FY2023 | -$7.15 | +78.5% |
| FY2022 | -$33.25 | -2969.3% |
| FY2021 | -$1.08 | +25.7% |
| FY2020 | -$1.46 | +15.0% |
| FY2019 | -$1.71 | +90.4% |
| FY2018 | -$17.81 | -48.6% |
| FY2017 | -$11.99 | +72.6% |
| FY2016 | -$43.70 | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026